Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Black Diamond Therapeutics, Inc. - Common Stock
(NQ:
BDTX
)
2.820
+0.040 (+1.44%)
Streaming Delayed Price
Updated: 12:12 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Black Diamond Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
December 03, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
December 02, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 06, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 06, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
↗
October 10, 2025
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
Via
Benzinga
Black Diamond (BDTX) Q2 Loss Narrows 47%
↗
August 07, 2025
Via
The Motley Fool
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 07, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
May 29, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
March 31, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
These stocks have an unusual volume in today's session
↗
March 21, 2025
These stocks have an unusual volume in today's session
Via
Chartmill
Unusual volume stocks in Thursday's session
↗
March 20, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
Via
Chartmill
These stocks are the most active in today's session
↗
March 19, 2025
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
Via
Chartmill
What's going on in today's session
↗
March 19, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High
↗
March 19, 2025
As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 19, 2025
Via
Benzinga
Wednesday's session: gap up and gap down stocks
↗
March 19, 2025
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
Black Diamond Therapeutics Inks Licensing Pact With French Pharma Firm Servier For Its Early-Stage Cancer Drug Worth Over $700 Million
↗
March 19, 2025
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone...
Via
Benzinga
Discover the top movers in Wednesday's pre-market session.
↗
March 19, 2025
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
March 19, 2025
Via
Benzinga
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
March 19, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 06, 2025
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
↗
January 13, 2025
Via
Benzinga
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 05, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
November 01, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
October 07, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements
September 23, 2024
Via
AB Newswire
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
↗
September 23, 2024
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows...
Via
Benzinga
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
September 23, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
September 22, 2024
From
Black Diamond Therapeutics, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
